Open AccessCEACAM6 Is a Novel Biomarker in Pancreatic Adenocarcinoma and PanIN Lesions
Author(s) -
Mark Duxbury,
Evan Matros,
Thomas E. Clancy,
Gerald Bailey,
Michael Doff,
Michael J. Zinner,
Stanley W. Ashley,
Anirban Maitra,
Mark Redston,
Edward E. Whang
Publication year - 2005
Publication title -
annals of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.153
H-Index - 309
eISSN - 1528-1140
pISSN - 0003-4932
DOI - 10.1097/01.sla.0000154455.86404.e9
Subject(s) - medicine , adenocarcinoma , pancreatic cancer , pancreatic intraepithelial neoplasia , carcinoembryonic antigen , oncology , pathology , tissue microarray , immunohistochemistry , cancer research , cancer , pancreatic ductal adenocarcinoma
The purpose of this study was to test the hypothesis that CEACAM6 expression is an indicator of adverse pathologic features and clinical outcome in pancreatic adenocarcinoma.